Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 1.00 |
| ▸ | CNR2 | P34972 | 6/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30510967 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL13253299 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3476144 | 1.00 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3476704 | 0.94 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3476702 | 0.94 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3477587 | 0.93 | CNR1 (0.89) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3477591 | 0.93 | CNR1 (0.89) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3474186 | 0.92 | CNR1 (0.87) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL13253309 | 0.92 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL3476532 | 0.92 | CNR1 (0.84) | CNR1CNR2CYP2D6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-20060115425-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2006-06-01 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250229109-A1 | MONITORING TISSUE PERMEABILITY DURING ULTRASOUND PROCEDURES | INSIGHTEC LTD (IL) | 2025-07-17 | — | — | US | disclosed |
| EP-4496618-A2 | MONITORING TISSUE PERMEABILITY DURING ULTRASOUND PROCEDURES | Insightec Ltd. (IL) | 2025-01-29 | — | — | EP | disclosed |
| CN-222305753-U | PET probe synthesis and quality control integrated equipment | 杭州吉蕊科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-119233843-A | Monitoring tissue permeability during ultrasound procedures | 医视特有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119034652-A | PET probe synthesis and quality control integrated equipment | 杭州吉蕊科技有限公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024020572-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PTSD | NEW YORK STEM CELL FOUNDATION, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023180811-A2 | MONITORING TISSUE PERMEABILITY DURING ULTRASOUND PROCEDURES | INSIGHTEC LTD. (IL) | 2023-09-28 | — | — | WO | disclosed |
| US-7754188-B2 | Radiolabeled cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754188-B2 | Radiolabeled cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-07-13 | — | — | US | disclosed |
| US-7754188-B2 | Radiolabeled cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20060115425-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR1 221/4885CNR2 204/4885CYP2D6 1028/4885 |
| US-20060115425-A1 | Substituted amides | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885CYP2D6 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.